HAEMONETICS CORP — Director's Dealing 2021

Sep 9, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2021-08-30

Reporting Person: Miller Laurie A. (SVP, Human Resources)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8199	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-qualified Stock Option (Right to Buy)	$56.57	2028-05-18	Common Stock (1793)		Direct
Non-qualified Stock Option (Right to Buy)	$103.37	2027-05-18	Common Stock (1227)		Direct
Non-qualified Stock Option (Right to Buy)	$98.03	2026-05-14	Common Stock (1246)		Direct
Non-qualified Stock Option (Right to Buy)	$93.52	2025-06-11	Common Stock (1332)		Direct

Footnotes

F1: 2,662 securities are in the form of unvested restricted stock units ("RSUs") issued pursuant to the Issuer's 2005 Long-Term Incentive Compensation Plan (as amended) or 2019 Long-Term Incentive Compensation Plan. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. 1,347 of such RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant, with shares vesting on various dates between May 2022 and May 2025. 1,315 of such RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant, with shares vesting in June 2022 and June 2023.

F2: Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F3: Reflects options granted on May 18, 2020 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F4: Reflects options granted on May 14, 2019 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F5: Reflects options granted on June 11, 2018 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.